# National Research Corporation (NRC) Stock Analysis: A Healthcare Data Firm with 51.24% ROE

- Link: https://www.directorstalkinterviews.com/national-research-corporation-nrc-stock-analysis-a-healthcare-data-firm-with-51-24-roe/4121249028
- Published: 2026-04-16T10:21:19+01:00
- Author: Madison Wilson

National Research Corporation (NRC), a prominent player in the Health Information
Services industry, offers insights and analytics to healthcare organizations across
the United States. With a market capitalization of $405.8 million, NRC stands out
in the healthcare sector, primarily due to its impressive Return on Equity (ROE)
of 51.24%. This figure is a strong indicator of the company’s efficiency in generating
profits from its shareholders’ equity, suggesting robust management performance.

The current stock price of NRC is $17.84, reflecting a slight price change of 0.80(
0.05%). The 52-week range, spanning from $10.13 to $22.48, highlights the stock’s
volatility and potential opportunities for investors who can time their entry and
exits wisely. Despite the lack of available valuation metrics like the P/E ratio,
price/book, and price/sales, NRC’s positive cash flow of $16.65 million is a testament
to its capability to generate liquidity and sustain operations.

Interestingly, NRC’s revenue growth has contracted by 4.60%, which may raise concerns
about the company’s ability to expand its market share or enhance its service offerings.
However, it’s crucial to consider the company’s strategic focus on integrating technology
with healthcare solutions. NRC’s offerings, such as the AI engine Huey, emphasize
innovation and a forward-thinking approach that could potentially offset the current
revenue decline.

The dividend yield of 3.14% is appealing for income-focused investors, but it’s 
also essential to note the high payout ratio of 104.00%. This suggests that NRC 
is distributing more in dividends than its earnings, which might not be sustainable
long-term without growth in earnings or adjustments in dividend policy.

As for analyst ratings, the absence of buy, hold, or sell ratings, along with the
lack of a defined target price range, indicates that analysts may be adopting a 
wait-and-see approach. The high RSI (14) of 77.23 suggests that the stock is overbought,
which might prompt a cautious stance among investors seeking to enter at a more 
favorable price point.

From a technical perspective, NRC’s stock is trading above both its 50-day and 200-
day moving averages, at $15.55 and $15.75 respectively. This upward trend is generally
positive, suggesting that the stock is in a bullish phase. However, the MACD and
Signal Line figures, at 0.30 and 0.35 respectively, imply a need for careful monitoring
as these indicators hint at potential shifts in momentum.

Investors interested in NRC should consider the company’s innovative solutions and
their applicability in the evolving healthcare landscape. With its headquarters 
in Lincoln, Nebraska, and a foundation dating back to 1981, National Research Corporation
has a long-standing presence and a reputation for delivering value through data-
driven insights. As the healthcare industry continues to adapt to technological 
advancements, NRC’s focus on experience management and community insights positions
it as a potential candidate for growth in the long term, despite current challenges
in revenue expansion.

Share on: